Trial
NCT06385262
TOP 2301: Neoadjuvant Chemo for NSCLC
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Duke University
Collaborators
Regeneron Pharmaceuticals
Condition
Non Small Cell Lung Cancer
Intervention
Alirocumab
Why stopped
Protocol is currently undergoing study design revisions and will re-open after amendment is IRB approved
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-06